Fast growing in oncology - Recensione dipendente - Director presso AstraZeneca

4,0
10 mar 2024
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Innovative pipelines both in-house and in-license, a lot of learning opportunities.

Svantaggi

Overwhelming workload in oncology, talent retention/new hires can't keep the exponential growth of portfolio in oncology.

Esplora altre recensioni su AstraZeneca

5,0
25 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Good products, great oncology pipeline

Svantaggi

Global leaders moving to US that have limited understanding of US environment

1,0
19 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

The page is friendly to make an application.

Svantaggi

As an experienced healthcare analytics and commercial leader, I applied to 104 U.S.-based positions at AstraZeneca between 2025 and 2026 that closely matched my background. Despite receiving interviews from peer organizations, I did not receive a single recruiter interaction. I fully understand the competitiveness of hiring, but such a complete lack of engagement raises questions about potential overreliance on AI screening or unintended bias.

Vedi recensioni per: Utile|Valutazione|Data|Tutto